INTRODUCTION
============

Colorectal cancer (CRC) is a health problem worldwide. CRC is expected to increase due to the growth and aging of the population, as well as the adoption of behaviors and lifestyles that increase the risk of dying \[[@b1-ir-2019-09179],[@b2-ir-2019-09179]\]. In Mexico, where CRC ranks fourth among the most common cancers, most cases are detected after 50 years of age, and the scenario is similar for both sexes. Therefore, the number of new cases and the mortality rates have increased consistently with the growing life expectancy, which currently presents a global public health problem \[[@b3-ir-2019-09179]\].

Some sociodemographic characteristics have been studied and have been correlated with survival in several types of cancer, including CRC. Some studies have pointed out that survival is influenced by social inequalities \[[@b4-ir-2019-09179]-[@b6-ir-2019-09179]\]. Likewise, the socioeconomic stratum, which affects access to early detection programs and determines the type of health service available \[[@b7-ir-2019-09179]\]. Similarly, lifestyle behaviors in rural area are considered risk factors for this type of cancer \[[@b8-ir-2019-09179]\]. Some countries, such as Brazil, have reported an increase in the incidence of CRC in areas of unequal social stratum and low levels of schooling \[[@b9-ir-2019-09179]\].

The important advances made in diagnostic and therapeutic techniques, together with prevention programs for early detection of malignancies in the preclinical phase, have contributed to improving the survival ratio \[[@b10-ir-2019-09179],[@b11-ir-2019-09179]\]. Recent studies have shown that tumors located in the right colon are associated with lower survival compared to those restricted to the left colon, as shown by Loupakis et al. \[[@b12-ir-2019-09179]\].

Long-term disease-free survival following the excision of polyps with metastasis observed due to the development in recent years of advanced surgical techniques. Differences in disease-free survival also depend on the chemotherapy regimen and planned cycles are completed \[[@b13-ir-2019-09179]\]. Polyp resection is indicated when base is between 2 to 2.5 cm \[[@b13-ir-2019-09179]\]. By colonoscopy it is possible to remove up to 70% of the polyps located in the colon and rectum \[[@b14-ir-2019-09179]\].

Several randomized controlled trials conducted to compare the effectiveness of a series of treatment protocols \[[@b14-ir-2019-09179],[@b15-ir-2019-09179]\]. Age and advanced stage colon cancer are considered predictive of early mortality, as well as disease characteristics such as having more than one positive lymph node, a poorly differentiated tumor and concomitant diseases \[[@b16-ir-2019-09179]\]. Chemoradiation is the treatment of choice in tumors located in the rectum. The survival rate improved in patients with stage III colon cancer \[[@b17-ir-2019-09179]\].

This study aimed to determine the probability of survival in patients with CRC and to identify the association between survival and low levels of schooling, low socioeconomic status, and location in a rural population, adjusting for the clinical and histologic stages of disease and the type of treatment.

METHODS
=======

1. Study Design and Patients
----------------------------

A retrospective open cohort study was conducted in which all patients diagnosed in the 2010 to 2016 period were included in the State Cancer Center, a tertiary care center, located in Xalapa, Veracruz-Mexico. The maximum and the minimum follow-up period was 60 and 24 months, respectively and the patients were classified as exposed or not exposed according to the level of schooling. The selection criteria were patients with a confirmed diagnosis of CRC who were 18 years or older, of either both sex and who resided in the state of Veracruz. Participants were selected based on information obtained by secondary sources, such as clinical records and information provided by the Department of Social Work. The monitoring included the time interval between the date of diagnosis and the date of the last consultation or the date of death from any cause. For the rest of the cohort, the follow-up time ended on December 31, 2016. This study was approved by the Research Ethics Committee of State Cancer Center, Secretary of Health of the State of Veracruz (approval No. SEIC-006-16). This study is a retrospective study using medical record review and so informed consent was waived.

2. Variables
------------

The main response variable was the survival of patients with CRC defined as the time between the confirmation of the diagnosis of CRC and the death of the patient. The death was verified through the death certificate provided by the social work coordination and by the records of the Epidemiological System and Death Statistics.

The predictor variables were a low level of schooling, defined as "less or equal" level of secondary schooling; socioeconomic status, defined as the number that indicates the social and economic position in which the patient's family is located; and the rural population, defined as the population with less than 2,500 inhabitants.

Other covariables recorded were tumor size, histological type and clinical stage of disease using the criteria of the American Joint Commission on Cancer and the World Health Organization (WHO). Sociodemographic variables that were also included were the type of diagnosis and treatment, the date of the last contact and the date of death, as well as the presence of associated pathologies. The criteria for socioeconomic classification were the following variables with their respective weight: family income (55%), job (10%), family expenses (10%), housing (20%), and family health (5%).

3. Scales and Questionnaires
----------------------------

Experts from the study's headquarters hospital and the Instituto Nacional de Oncología, located in Havana, Cuba, validated the collection card. The following information collected through the clinical file: diagnosis of CRC (histological tissue and colonoscopy). The date and cause of death were obtained from the death certificate.

The size of the sample was calculated from the results of a cohort study by Lejeune et al. \[[@b18-ir-2019-09179]\], where it was found that the survival of the subjects with a low level of education was 57.1% (HR, 0.73; 95 CI, 0.57--0.94). With the information mentioned above and considering a confidence level of 95% and a minimum power of 80%, the sample size calculated was 104 patients.

4. Statistical Analysis
-----------------------

Descriptive statistics were used for sociodemographic, clinical, and histological characteristics and those related to the treatment of the studied cohort. The survival analysis was calculated with the Kaplan-Meier method. Survival probabilities were compared for each possible prognostic factor using the log-rank test. Subsequently, the prognostic factors adjusted for possible confounders in a multivariate analysis using Cox regression, where the dependent variable was age, and the covariates were clinical stage, histological type, level of schooling, place of residence. The HRs and their respective 95% CIs were calculated. Losses during the monitoring were considered censored data and were contributed to the sum of the total person-time. The statistical package IBM SPSS statistics software (IBM Corp., Armonk, NY, USA), for Windows version 23.0, was used for analysis.

RESULTS
=======

Of the 323 patients initially considered, the following were excluded: 5 resided in another geographical area, 8 had recurrent CRC, and 5 had another type of cancer added to the primary malignancy. In total, the study sample consisted of 305 patients, mostly men, with a minimum and maximum age of 18 and 96 years, respectively. The population from rural areas predominated, had an educational level equal to or lower than the basic level, had mostly paid employment, and almost the entire population was registered at a low socioeconomic status ([Table 1](#t1-ir-2019-09179){ref-type="table"}).

The methods used to diagnose suspicion of CRC were, 66% colonoscopy, 20.5% imaging tests and 13.5% surgery. The frequency tumors stages were II 29%, III 30.6%, and IV 33.3%, principally located in the rectum and were greater than 5 centimeters. The liver was the organ most frequently affected by distant metastasis, and adenocarcinoma was the most common histological type ([Table 2](#t2-ir-2019-09179){ref-type="table"}).

The most frequent symptoms were colic (49.2%), combined with weight loss and rectal bleeding (43.6%), among other symptoms. The most frequent types of comorbidities were arterial hypertension (34.8%) and diabetes mellitus (28.3%). The most frequent treatment undergone was a combination of surgery with chemotherapy, as well as chemotherapy with oxaliplatin ([Table 2](#t2-ir-2019-09179){ref-type="table"}).

1. Survival Ratio
-----------------

The overall survival ratio for the cohort at 60 months of monitoring was 40%. A greater statistically significant survival was observed in patients \>65 years of age (*P*=0.03) who had a high level of education (*P*=0.02) ([Table 3](#t3-ir-2019-09179){ref-type="table"}). Those patients with an early clinical stage (*P*\<0.001) and without metastasis (*P*\<0.001) had a high probability of survival ([Table 4](#t4-ir-2019-09179){ref-type="table"}). When evaluating the types of treatment, when a combination included surgical treatment, survival was 41% (*P*=0.012) ([Fig. 1](#f1-ir-2019-09179){ref-type="fig"}).

2. Prognostic Factors
---------------------

After adjusting for age (\<65 years and ≥65 years), the following variables showed a significant association with survival: low level of schooling, tumors in an advanced clinical stage and the presence of metastasis, all of which increased the risk of dying due to poor prognostic factors ([Table 5](#t5-ir-2019-09179){ref-type="table"}).

DISCUSSION
==========

There is a wide variation in survival between different geographical areas; due to differences in exposure to risk factors for CRC, access to cancer diagnosis and type of treatment. As shown in our results, the 5-year global survival was very low, similar to that reported in other Latin American countries, such as Chile and Colombia \[[@b19-ir-2019-09179],[@b20-ir-2019-09179]\].

Similarly, these inconsistencies in survival attributed to the inequalities in socioeconomic status and the geographic area of origin \[[@b9-ir-2019-09179]\]. Even the low level of schooling related to an increased risk of CRC \[[@b21-ir-2019-09179]\]. A low 37% survival in the population was associated with a low level of education, which, in the multivariate analysis, was a poor prognostic factor (HR, 7.46; 95% CI, 1.02--54.7) in our cohort study. Similar results were reported by Cavalli-Björkman et al. \[[@b22-ir-2019-09179]\]. In contrast, a recent study suggested that a high level of schooling was a protective factor against CRC (HR, 0.61; 95% CI, 0.39--0.92), compared to illiterate patients \[[@b23-ir-2019-09179]\]. Additionally, the education level was associated with the histological type of CRC and with the age of the subject in that, the young people developed aggressive tumors according to the histological differentiation \[[@b24-ir-2019-09179],[@b25-ir-2019-09179]\].

The clinical stage is still considered an element that can guide therapeutic treatment and constitutes a prognostic factor in patients \[[@b26-ir-2019-09179]\]. In the study in general, more than 60% of tumors diagnosed in advanced stages, implied a lower survival and a higher risk of dying from CRC. In recent reports, the International Agency for Research on Cancer showed a high incidence of advanced stages of CRC not only in developing countries but also in developed countries \[[@b1-ir-2019-09179]\]. This is the case in Mexico and specifically for the cohort under study with a high degree of marginalization. In agreement, other studies conducted in populations of low socioeconomic status or located in remote areas showed a high incidence of advanced stage disease, revealing the lack of early detection programs and, in some contexts, poorer standards of care and difficulty in accessing screening tests \[[@b1-ir-2019-09179],[@b9-ir-2019-09179],[@b23-ir-2019-09179],[@b26-ir-2019-09179]\].

In addition, the same effect observed in our results of advanced stage disease: a very low survival of 22%, unlike the rate of survival in the early stages (68%), similarity with what has been reported for this type of cancer \[[@b27-ir-2019-09179],[@b28-ir-2019-09179]\]. These data indicate CRC diagnosis at late stage, reducing the probability of survival, which suggests the need to increase efforts for detection in early stages.

In the multivariate analysis ([Table 5](#t5-ir-2019-09179){ref-type="table"}), stages III and IV emphasized as poor prognostic factors with an HR of 2.24 (1.15--4.36), which coincides with the findings by Sharkas et al. \[[@b27-ir-2019-09179]\] who reported, when subdividing the tumor into regional and distant metastasis (HR, 1.8; 95% CI, 1.6--3.7; HR, 4.5; 95% CI, 3.7--5.1, respectively).

Our results, consistent with the current literature, have shown that the presence of metastasis shown to be an important predictor of recurrence and poor survival and was the main cause of mortality in patients with CRC \[[@b29-ir-2019-09179]\]. We observed that a significant number of these patients experienced early metastasis in the liver, followed by metastasis to the bone and the lung. Due to the location, size, and extent of metastasis, no patient survived after 5 years. The prognosis and clinical characteristics of bone metastasis in CRC poorly studied due to their low incidence and insufficient research \[[@b30-ir-2019-09179],[@b31-ir-2019-09179]\].

The main factor linked to improved survival in CRC, according to the literature, is the progress that made with adjuvant treatments after surgery \[[@b32-ir-2019-09179],[@b33-ir-2019-09179]\]. While undergoing some surgical procedures they showed a better effect on survival (47%) than not undergoing surgery (27%) (*P*=0.002) ([Fig. 1E](#f1-ir-2019-09179){ref-type="fig"}). However, 5-fluorouracil monotherapy was the treatment with the highest survival rates. Surgery in this type of neoplasm is very invasive, and the older the patient, the greater the risk of developing complications, which is also associated with the patient's living conditions.

In contrast, we identified that the combination of surgical treatment and chemotherapy showed the best survival at 38%. However, another study showed a survival of only 58.3% with surgery, and survival in patients who received adjuvant chemotherapy increased to 83.4% \[[@b33-ir-2019-09179]\]. Analogous results reported for localized tumors that were operated on and treated with 5FU postoperatively, and they showed a great benefit in stage III \[[@b32-ir-2019-09179]\]. The studies described previously conducted in developed countries, such as Japan and the United States, where prevention programs implemented and living conditions differ from those of our study cohort \[[@b33-ir-2019-09179]\].

CRC represents a large global burden that predicted to increase due to the growth and aging of the population because of the adoption of behaviors and lifestyles that increase the risk of developing CRC. By recognizing this growing problem in Mexico and implementing consistent monitoring (pre- and postsurgical), the poor survival associated with CRC and the rate of recurrence could help spur efforts to optimize management by increasing the availability of effective access to timely detection. Intensifying educational protocols in the management and control of CRC risk factors and disseminating information that will trigger a social response in accordance with the available conditions and resources.

Finally, the predictor with the highest association to low survival was "less or equal" to the level of secondary schooling (HR, 7.6; 95% CI, 1.1--54.7), which was independent of other covariates, such as occupation or profession and economic income; the latter was not analyzed since all patients reported the lowest economic level. However, other indicators were included that gave a good approximation of the socioeconomic status.

Implementing a screening program and developing additional strategies based on the population at risk of CRC would reduce the gap between the survival of patients with high and low schooling, as well as decrease the incidence of CRC in the coming years. In addition, these strategies could reduce the degree of disease progression in preclinical and clinical patients, thus accelerating treatment and reflecting favorable changes in survival.

The strengths of the present study were the inclusion of the sample size, the collection of standardized data and a limited loss during follow-up. Information bias was reduced by corroborating all clinical records. An approved criterion when making multidisciplinary decisions. The main limitations of this study include the retrospective nature of this study and the restrictions inherent to the quality of the information in the clinical records that belong to the heterogeneous population and the use of different diagnostic methods. Our study had another limitation: it included a percentage of unclassified patients from a public institution.

In conclusion, regarding the variables that influenced survival, the presence of metastasis, advanced disease and low education were determined to be predictive in more than half of the cases studied that were diagnosed in advanced stages (III-IV) and had a lower overall survival. Possible explanations include late diagnosis, barriers to timely access to care and effective treatment and underlying comorbidities.
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###### 

Sociodemographic and Clinical Characteristics of the Cohort Participants (n=305)

  Variable                                                        No. of patients (%)
  --------------------------------------------------------------- ---------------------
  Age (yr)                                                        
   \< 65                                                          208 (68.2)
   ≥ 65                                                           97 (31.8)
  Sex                                                             
   Male                                                           178 (58.4)
   Female                                                         127 (41.6)
  Place of origin                                                 
   Rural                                                          196 (64.3)
   Urban                                                          109 (35.7)
  Occupation                                                      
   Worker                                                         163 (53.4)
   Housework                                                      116 (38.1)
   Unemployed                                                     26 (8.5)
  Clinical stage^[a](#tfn1-ir-2019-09179){ref-type="table-fn"}^   
   Local                                                          132 (51.2)
   Regional                                                       40 (15.5)
   Distant                                                        86 (33.3)
  Level of education                                              
   Illiterate                                                     132 (43.3)
   Primary/secondary education                                    152 (49.8)
   High school/university                                         21 (6.9)
  Location of the tumor                                           
   Blind                                                          40 (13.1)
   Ascending+descending colon                                     81 (26.6)
   Transverse colon                                               22 (7.2)
   Sigmoid                                                        52 (17.0)
   Straight                                                       110 (36.1)
  Tumor size (cm)                                                 
   ≤5                                                             97 (34.8)
   \> 5                                                           182 (65.2)
  Metastatic lymph nodes                                          
   No                                                             250 (82.0)
   Yes                                                            55 (18.0)
  Location of metastasis                                          
   Liver                                                          41 (41.4)
   Lung                                                           15 (15.2)
   Bone                                                           5 (5.0)
   Others                                                         38 (38.4)

Unclassified=47 patients.

###### 

Sociodemographic and Clinical Characteristics of the Cohort Participants

  Variable                             Education    *P*-value^[a](#tfn2-ir-2019-09179){ref-type="table-fn"}^   
  ------------------------------------ ------------ ---------------------------------------------------------- ----------
  Age (yr)                                                                                                     0.070
   \< 65                               190 (66.9)   18 (87.5)                                                  
   ≥ 65                                94 (33.1)    3 (14.3)                                                   
  Sex                                                                                                          0.170
   Male                                167 (58.8)   11 (52.4)                                                  
   Female                              117 (41.2)   10 (47.6)                                                  
  Place of origin                                                                                              0.002
   Rural                               189 (66.5)   7 (33.3)                                                   
   Urban                               95 (33.5)    14 (66.7)                                                  
  Occupation                                                                                                   0.730
   Worker                              151 (49.5)   12 (57.1)                                                  
   Unemployed                          55 (50.5)    9 (42.9)                                                   
  Clinical stage                                                                                               0.960
   Early                               87 (30.6)    6 (28.6)                                                   
   Advanced                            153 (53.9)   12 (57.5)                                                  
   Unclassified                        44 (15.5)    3 (14.3)                                                   
  Location of the tumor                                                                                        0.230
   Blind                               38 (13.5)    2 (9.5)                                                    
   Ascending+descending colon          77 (27.3)    4 (19.0)                                                   
   Transverse colon                    17 (7.4)     4 (19.0)                                                   
   Sigmoid                             47 (16.7)    4 (19.0)                                                   
   Straight                            103 (36.5)   7 (33.3)                                                   
  Tumor size (cm)                                                                                              0.190
   2--5                                93 (35.8)    4 (21.1)                                                   
   \> 5                                167 (64.2)   15 (78.9)                                                  
  Metastatic lymph nodes                                                                                       \< 0.001
   No                                  239 (84.2)   11 (52.4)                                                  
   Yes                                 45 (15.8)    10 (47.6)                                                  
  Location of metastasis                                                                                       0.030
   Liver                               40 (41.7)    1 (33.3)                                                   
   Lung                                13 (13.5)    2 (66.7)                                                   
   Others                              43 (44.8)    0                                                          
  Type of treatment (n = 261)                                                                                  0.170
   Surgery                             18 (18.2)    1 (5.0)                                                    
   Chemotherapy                        23 (23.2)    5 (25.0)                                                   
   Radiotherapy                        1 (1.0)      1 (5.0)                                                    
   Surgery and chemotherapy            37 (37.4)    10 (50.0)                                                  
   Surgery and radiotherapy            3 (3.0)      1 (5.0)                                                    
   Chemotherapy and radiotherapy       7 (7.1)      1 (5.0)                                                    
   Surgery+chemotherapy+radiotherapy   10 (10.1)    1 (5.0)                                                    
  Type of chemotherapy (n = 182)                                                                               0.590
   Neoadjuvant                         61 (33.5)    5 (27.8)                                                   
   Adjuvant                            121 (66.5)   13 (72.2)                                                  
  Scheme of chemotherapy (n = 163)                                                                             0.960
   Oxaliplatin                         59 (39.6)    5 (35.7)                                                   
   XELOX                               37 (24.8)    4 (28.6)                                                   
   FOLFOX                              15 (10.1)    2 (14.3)                                                   
   5 FU                                20 (13.4)    16 (14.3)                                                  
   Others                              18 (12.1)    1 (7.1)                                                    

Comparison of proportions using chi square (Fisher exact test was used when necessary).

XELOX, capecitabine (Xeloda) and oxaliplatin; 5 FU, 5-fluorouracil; FOLFOX, oxaliplatin, 5-FU, and leucovorin.

###### 

Survival According to Sociodemographic Characteristics (n=305)

  Variable                 No. of subjects   2-Year survival rate (%)^[a](#tfn3-ir-2019-09179){ref-type="table-fn"}^   5-Year survival rate (%)^[a](#tfn3-ir-2019-09179){ref-type="table-fn"}^   *P*-value^[b](#tfn4-ir-2019-09179){ref-type="table-fn"}^
  ------------------------ ----------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------
  Age (yr)                                                                                                                                                                                       0.03
   \< 65                   208               68                                                                        48                                                                        
   ≥ 65                    97                56                                                                        28                                                                        
  Sex                                                                                                                                                                                            0.62
   Male                    178               67                                                                        44                                                                        
   Female                  127               61                                                                        38                                                                        
  With partner or spouse                                                                                                                                                                         0.89
   Yes                     111               65                                                                        45                                                                        
   Do not                  194               63                                                                        33                                                                        
  Provenance zone                                                                                                                                                                                0.85
   Urban                   109               65                                                                        43                                                                        
   Rural                   196               63                                                                        39                                                                        
  Level of education                                                                                                                                                                             0.02
   Low                     284               62                                                                        37                                                                        
   High                    21                86                                                                        86^[c](#tfn5-ir-2019-09179){ref-type="table-fn"}^                         
  Employment situation                                                                                                                                                                           0.34
   Worker                  163               70                                                                        42                                                                        
   Unemployed              142               58                                                                        36                                                                        
  Socioeconomic level                                                                                                                                                                            NA^[d](#tfn6-ir-2019-09179){ref-type="table-fn"}^
   Low                     295               63                                                                        38                                                                        
   High                    10                99.9                                                                      99.9                                                                      

Kaplan-Meier method.

Log-rank test.

Maximum survival of 58 months.

NA: not applicable because some of the categories of the variables showed an expected value less than 5.

###### 

Survival According to Tumor Characteristics and Treatment

  Variable                 No.   2-Year survival rate (%)^[a](#tfn7-ir-2019-09179){ref-type="table-fn"}^   5-Year survival rate (%)^[a](#tfn7-ir-2019-09179){ref-type="table-fn"}^   *P*-value^[b](#tfn8-ir-2019-09179){ref-type="table-fn"}^
  ------------------------ ----- ------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------
  Clinical stage                                                                                                                                                                     \< 0.001
   Early                   93    82                                                                        68                                                                        
   Advanced                165   56                                                                        22                                                                        
  Tumor location                                                                                                                                                                     0.700
   Descendent colon        21    75                                                                        75                                                                        
   Blind                   40    75                                                                        55^[c](#tfn9-ir-2019-09179){ref-type="table-fn"}^                         
   Transverse colon        21    63                                                                        50^[d](#tfn10-ir-2019-09179){ref-type="table-fn"}^                        
   Rectum                  110   61                                                                        46                                                                        
   Ascendant colon         60    60                                                                        33                                                                        
   Sigmoid colon           51    84                                                                        19                                                                        
  Tumor size (cm)                                                                                                                                                                    0.700
   \< 2                    11    60                                                                        45^[e](#tfn11-ir-2019-09179){ref-type="table-fn"}^                        
   2--5                    86    66                                                                        49                                                                        
   \> 5                    182   65                                                                        39                                                                        
  Metastatic lymph node                                                                                                                                                              0.110
   0                       249   60                                                                        42                                                                        
   1--3                    29    68                                                                        34^[f](#tfn12-ir-2019-09179){ref-type="table-fn"}^                        
   ≥ 4                     26    88                                                                        0                                                                         
  Presence metastasis                                                                                                                                                                \< 0.001
   Negative                204   71                                                                        57                                                                        
   Positive                101   47                                                                        0                                                                         
  Distant metastases                                                                                                                                                                 0.008
   Lung                    15    74                                                                        48^[g](#tfn13-ir-2019-09179){ref-type="table-fn"}^                        
   Liver                   41    24                                                                        0^[h](#tfn14-ir-2019-09179){ref-type="table-fn"}^                         
   Lung and liver          9     0                                                                         0                                                                         
   Bone                    5     53                                                                        0                                                                         
   Others                  29    57                                                                        0                                                                         
  Histologic grade                                                                                                                                                                   0.170
   Grade 1                 195   24                                                                        41                                                                        
   Grade 2                 68    70                                                                        39                                                                        
   Grade 3                 32    50                                                                        37^[i](#tfn14-ir-2019-09179){ref-type="table-fn"}^                        
  Type of chemotherapy                                                                                                                                                               0.150
   Adjuvant                61    61                                                                        34                                                                        
   Neoadjuvant             121   70                                                                        40                                                                        
  Scheme of chemotherapy                                                                                                                                                             0.320
   5 FU                    22    73                                                                        63                                                                        
   Capecitabine            16    57                                                                        57                                                                        
   Oxaliplatin             64    70                                                                        43                                                                        
   FOLFOX                  17    62                                                                        31                                                                        
   XELOX                   41    68                                                                        0                                                                         
   Others                  3     50                                                                        0                                                                         

Kaplan-Meier method.

Log-rank test.

Maximum survival of 56 months.

Maximum survival of 49 months.

Maximum survival of 42 months.

Maximum survival of 58 months.

Maximum survival of 55 months.

Maximum survival of 56 months.

Maximum survival of 56 months.

5 FU, 5-fluorouracil; FOLFOX, oxaliplatin, 5-FU, and leucovorin; XELOX, capecitabine (Xeloda) and oxaliplatin.

###### 

Multivariate Analysis in Variables of Factors Associated with the Survival of Colorectal Cancer

  Covariable                      Unadjusted model   *P*-value   Adjusted model    *P*-value
  ------------------------------- ------------------ ----------- ----------------- -----------
  Age (yr)                                                                         
   \< 65                          Reference                      Reference         
   ≥ 65                           1.4 (0.8--2.2)     0.20        \-                
  Schooling                                                                        
   High                           Reference                      Reference         
   Low                            7.3 (1.0--53.3)    0.05        7.6 (1.1--54.7)   0.04
  Origin                                                                           
   Urban                          Reference                      Reference         
   Rural                          0.8 (0.5--1.2)     0.20        \-                0.19
  Clinical stage                                                                   
   Early                          Reference                      Reference         
   Advanced                       2.1 (1.1--4.0)     0.03        2.1 (1.2--4.0)    0.02
  Metastasis                                                                       
   Absence                        Reference                      Reference         
   Presence                       1.7 (1.02--2.9)    0.04        1.8 (1.1--2.9)    0.03
  Treatment 1                                                                      
   Without surgery                Reference                      Reference         
   With surgery                   0.9 (0.5--1.7)     0.81        \-                0.26
  Treatment 2                                                                      
   With surgery chemotherapy      Reference                      Reference         
   Without surgery chemotherapy   0.7 (0.4--1.4)     0.29        \-                0.09
